Deprax

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deprax

What is Deprax? (Trazodone)

Property Description
Active ingredient Trazodone Hydrochloride
Form Oral tablet (usually scored)
Pharmacological class Serotonin Antagonist and Reuptake Inhibitor (SARI)
Common use Treating Major Depressive Disorder and Insomnia
Status Prescription-only (Rx)

Deprax is a brand name for the generic prescription medication trazodone hydrochloride. Trazodone is classified as a Serotonin Antagonist and Reuptake Inhibitor (SARI), a distinct class of antidepressant that modulates the brain’s neurotransmitter system, specifically targeting serotonin.

Trazodone is clinically recognized for its effectiveness in the primary treatment of major depressive disorder (MDD). This indicates that the medication is a validated option for managing emotional and psychological distress related to MDD.

A key differentiating feature of trazodone is its notable sedative properties. Unlike many other antidepressants, research has confirmed its unique efficacy as a sleep aid, especially in individuals with comorbid depression. This dual-action profile makes it a valuable choice for patients whose depression is accompanied by significant sleep disturbances.

The drug is an oral tablet and is a prescription-only (Rx) medicine, requiring professional medical oversight due to its mechanism and potential side effects. The tablets are often scored, allowing physicians to precisely adjust the dosage to achieve different therapeutic goals.

Regulatory References

  1. NIH MedlinePlus Trazodone

What side effects are possible with Deprax?

Possible Side Effects and Safety Information

The safety profile of Deprax (Trazodone) is organized by regulatory authorities to classify potential adverse reactions based on their frequency and the physiological systems affected. This section is strictly descriptive of the facts documented in official labeling.

Adverse effects are categorized using standard international frequency definitions. The most Very Common documented reactions, affecting more than 1 in 10 individuals, include Drowsiness/Sedation, Dizziness, Headache, and Dry Mouth. Effects listed as Common include Nausea, Vomiting, Constipation, Fatigue, and Postural/Orthostatic Hypotension, which is a drop in blood pressure upon standing.


Serious Adverse Reactions and Safety Constraints

Official regulatory documents highlight the potential for serious adverse reactions, which are typically rare but clinically significant. These include Priapism (a prolonged, painful erection), severe Liver Function Disorders, and rare Blood Dyscrasias (e.g., Agranulocytosis). The potential for Serotonin Syndrome is also noted, especially when the drug is used with other serotonergic medicines.

Safety notes specify time-related patterns, documenting that effects such as sedation and the risk of suicidal ideation may be more noticeable at the start of treatment or following dosage changes. Specific warnings are documented for special populations: Older Adults may be more susceptible to Postural Hypotension, and there is an increased risk of suicidal thinking and behavior noted for young adults. The drug is Contraindicated in certain contexts, such as the initial recovery period following a myocardial infarction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Symptoms and Manifestations

An overdose of Deprax (trazodone hydrochloride) may result in a range of symptoms, most frequently presenting as drowsiness and vomiting. However, more severe and potentially life-threatening manifestations have been reported, even when the drug is taken alone. These severe reactions can include seizures, respiratory arrest, and serious ECG changes, such as QT prolongation, which indicates an electrical disruption in the heart's rhythm. Additionally, a prolonged, painful erection (priapism) is a possible serious complication.

Risk Factors and Required Actions

The risk of severe overdose is significantly increased when Deprax is ingested concurrently with other central nervous system depressants, including alcohol or specific sedatives, with documented cases of death under these circumstances. There is no specific antidote for a Deprax overdose, and treatment focuses on supportive medical care, often requiring close cardiac monitoring.

When to Seek Immediate Medical Attention

Immediate emergency medical attention is required if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. In any suspected overdose situation, contact a certified Poison Control Center or immediately call emergency services (911 in the U.S.). When managing an overdose, healthcare providers must consider the strong possibility of multiple substances being involved.

Therapeutic Uses of Deprax

What Deprax Treats: Main Uses and Benefits

Deprax is considered relevant for managing symptoms in Major Depressive Disorder (MDD), a condition characterized by periods of heightened symptoms, including persistent depressed mood and overall dysphoria. The medication assists with easing the overall symptom load of these affective manifestations, generally contributing to improved day-to-day comfort. It is applicable in contexts marked by increased discomfort or tension.

A key area of utility is relevant for easing Insomnia and related sleep disturbances, which often accompany depression or anxiety. It is relevant when symptoms create noticeable interference with functional stability, specifically helping with difficulty falling asleep and staying asleep throughout the night. The medication is commonly used to help with symptoms in conditions presenting with MDD, anxiety, and sleep disturbances.

The primary benefit supports the patient during difficult episodes by helping with sleep-related distress, which may assist with maintaining functional stability by reducing symptoms that interfere with daily functioning. The drug is considered relevant when supportive symptom management is appropriate in complex patient scenarios, such as when depression co-occurs with inner tension.


Quick Fact: Symptomatic Support for Sleep Disturbances The medication is frequently used to manage sleep disturbances, and may assist with maintaining functional stability during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Deprax? (Trazodone)

Official regulatory guidelines define specific populations who are eligible to use Deprax, as well as groups who are strictly excluded or require conditional use.


Populations Excluded from Use

Deprax is contraindicated in patients with a known hypersensitivity to the medicine or its components. It must not be used concurrently with, or within 14 days of discontinuing, a Monoamine Oxidase Inhibitor (MAOI). The medicine is also not recommended for patients in the acute recovery phase of a myocardial infarction or those suffering from alcohol or hypnotic intoxication.

Eligibility by Age and Health Status

The medicine is approved for use in adults (18 years and older). Use in children and adolescents under 18 years is not recommended as safety and efficacy have not been established. Older adults may use the medicine but require caution due to increased sensitivity to adverse effects.

Conditional Use is required for patients with severe hepatic (liver) or renal (kidney) impairment, and for those with pre-existing cardiac disease or a history of epilepsy.

Pregnancy and Lactation

Use during pregnancy is restricted, particularly in the third trimester, and the medicine is not recommended for women who are breastfeeding as it is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Deprax (Trazodone) has officially documented interaction patterns that are defined by its metabolic clearance and pharmacodynamic activity, as stated in regulatory prescribing information. The primary constraints involve combinations that are strictly contraindicated or require special regulatory attention.

Contraindicated and Restricted Combinations

Classification Interacting Substances
Contraindicated Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue.
Timing Rule A 14-day separation period is mandatory between discontinuing an MAOI and starting Deprax, and vice versa.

Pharmacokinetic and Pharmacodynamic Effects

The most significant interaction domain involves metabolic modulation via the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) can increase the plasma concentration of Trazodone, while strong inducers (e.g., carbamazepine) can cause a decrease.

Pharmacodynamic interactions involve substances that share similar effects, such as Serotonergic Drugs (e.g., SSRIs), which increase the risk of Serotonin Syndrome. Trazodone may also enhance the effects of Central Nervous System (CNS) Depressants, including alcohol, and increase the risk of abnormal bleeding when combined with antiplatelet or anticoagulant agents. Additionally, concomitant use with Digoxin or Phenytoin may result in increased serum levels of these two medications.

Mechanism of Action

Suppression of CNS Arousal Pathways

The primary physiological action of Deprax begins with the rapid, high-affinity antagonism (blockade) of three key central nervous system (CNS) receptors: the 5-HT2A Serotonin Receptor, the H1 Histamine Receptor, and the alpha1-Adrenergic Receptor. This simultaneous blockade rapidly suppresses the signaling cascades that drive wakefulness and alertness, translating immediately into a reduction in excitability and CNS arousal signaling, supporting the transition to a decreased state of wakefulness.


Gradual Synaptic Serotonin Modulation

The secondary mechanism involves weak inhibition of the Serotonin Transporter (SERT), which slows the reabsorption of serotonin (5-HT) back into the presynaptic neuron. This action, combined with partial agonism at the mathbf5-HT1A receptor, results in a sustained, modest elevation of synaptic 5-HT over time. These gradual changes initiate neuroadaptive changes within neural circuits, modulating neuronal signaling.


Mechanism Limitations and Competitive Binding

The two main mechanisms display a concentration-dependent hierarchy. The powerful arousal blockade mechanism dominates the pharmacological profile at lower concentrations, functionally constraining the less potent SERT inhibition mechanism that requires higher plasma levels to be relevant. Furthermore, the active metabolite, mathbfmCPP, introduces a counteracting serotonergic signal by acting as a 5-HT2C agonist, which complicates the resulting neurochemical activity.

Dosage and Administration Information

How to Use Deprax: Official Administration Guidelines

Deprax (trazodone) is administered exclusively via the oral route as scored tablets for flexible dosing. The use of immediate-release (IR) and extended-release (ER) formulations dictates the precise administration conditions.


Dosing and Schedule

The standard initial regimen for an adult typically begins at 150 mg per day; this is administered in divided doses for the IR tablet or as a single dose at bedtime for the ER tablet. The total dose may be increased incrementally (titration), with increases occurring every three to four days, based on the specific formulation. The maximum daily dose for outpatients receiving IR tablets generally should not exceed 400 mg.

Administration Specifics

Timing in relation to food is formulation-dependent. Immediate-release tablets should be taken shortly after a meal or light snack to optimize absorption and reduce potential intolerance. In contrast, certain extended-release formulations are required to be taken on an empty stomach. Tablets can be broken along the score line to aid dosing but must not be chewed or crushed.

Population and Procedural Rules

For older or frail adults, the initial starting dose is typically lower, such as 100 mg per day in divided doses, with the total daily amount generally not exceeding 300 mg. The use of Deprax in the pediatric population (under 18 years of age) is not recommended due to insufficient data. Treatment must not be stopped abruptly; instead, the dosage must be gradually reduced (tapered) under professional guidance to conclude the course of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deprax (Trazodone)


Evidence for Use in Major Depressive Disorder (MDD)

This segment summarizes the pivotal Randomized Controlled Trials (RCTs) was studied for short-term effects on adult patients diagnosed with Major Depressive Disorder. These studies was evaluated in adult patients and compared the drug against an inactive substance or against other existing antidepressant medications. The primary focus of these trials was to monitor the measurement of depressive symptom intensity over the observed time using standardized rating scales.

Regulatory findings describe patterns observed in the studies where measurements of overall depressive symptom intensity evolved in the observed populations during the short-term study periods. Comparative research examined measurements of symptom patterns relative to those seen with other antidepressant classes. A key limitation noted in the research is that the measured difference in symptom scores compared to placebo may be modest in some registration trials. The results apply only to the populations studied, and the research does not determine whether an individual will respond similarly.


Evidence for Use in Sleep Disturbances and Insomnia

This part outlines the studies, including meta-analyses and RCTs, that research examined for sleep-related issues. Research was studied for conditions associated with acute or disruptive episodes, such as insomnia and sleep disturbances, that often accompany conditions like depression. Researchers monitored outcomes using two types of measurements: patient-reported outcomes describing perceived discomfort and objective sleep parameters measured in laboratory settings.

Research highlights findings describing patterns observed in the studies where patient-reported outcomes describing perceived discomfort related to sleep quality and nocturnal awakenings were measured. Findings related to objective sleep parameters showed some variability; some reports suggest that objective measurements of the total time spent asleep may show limited change, even when findings help contextualize how patients reported their experience.


Long-Term Studies and Durability of Response

Research specifically exploring the long-term effects are not fully established and is less extensive than the acute efficacy data. The majority of the core evidence used for initial regulatory review was observed in short-term research scenarios, typically spanning only a few months. This short follow-up duration was limited and means that data for certain groups remain insufficient regarding the maintenance of effect and the durability of any observed changes over many months.

Frequently Asked Questions (FAQ)

Common questions about Deprax (FAQ)


Q: How long does it typically take for Deprax to start working?

A: According to official prescribing information, peak plasma concentrations (the highest level of the medicine in the blood) are typically reached within one hour after taking an immediate-release oral dose. However, the timeframe for an individual to notice the full therapeutic effects may take longer and can vary from patient to patient.


Q: Does Deprax cause weight gain or loss?

A: Clinical trial data lists weight loss as an infrequent side effect of Deprax. While changes in body weight are not listed among the most common adverse reactions, regulatory guidance suggests reporting significant changes in weight to the prescriber. Official documents indicate that weight gain may also occur.


Q: What happens if I forget to take a dose of Deprax?

A: General patient instructions often advise taking a missed dose as soon as remembered. If the time is close to that of the next scheduled dose, the official guidance often suggests skipping the dose rather than doubling up. This specific procedure is defined in the drug's patient instructions and should be consulted.


Q: What should I do if a side effect of Deprax bothers me?

A: Regulatory guidance requires patients to report any side effects that bother them to their healthcare professional. Serious or life-threatening reactions, such as signs of liver problems or prolonged erections (Priapism), are recognized as requiring emergency medical evaluation.


Q: How long does Deprax stay in your system after you stop taking it?

A: The time it takes for a medicine's concentration to fall by half is called the elimination half-life. Official pharmacokinetic data documents that the half-life of Trazodone (the active ingredient in Deprax) for the immediate-release formulation is between 4 and 15 hours.


Q: Does Deprax require regular blood tests or monitoring?

A: Official labeling notes the rare potential for serious adverse reactions such as severe liver function disorders and blood dyscrasias (disorders of the blood components). Due to these risks, a healthcare provider may determine that monitoring or blood tests are necessary if a patient has pre-existing risk factors or shows signs of symptoms.


Q: Is a metallic taste in the mouth a possible side effect of Deprax?

-A: Yes, official side effect listings note that an unpleasant taste in the mouth is a less common reaction associated with the use of Trazodone. This is distinct from the most frequently reported side effects like drowsiness or dry mouth.


Q: Does Deprax carry a Black Box Warning?

A: Yes, official FDA prescribing information indicates that Trazodone carries a Boxed Warning. This warning highlights the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) during short-term studies, particularly when starting treatment or changing dosage.


Q: Is it safe to drive while taking Deprax?

A: Official warnings state that Trazodone has the potential to impair an individual’s judgment, thinking, and motor skills. Official warnings note the potential for impairment; therefore, caution is warranted when operating machinery or driving until an individual is aware of the drug's effects.


Q: Do studies suggest Deprax is safe for long-term use?

A: Regulatory data for the treatment of Major Depressive Disorder is primarily based on short-term clinical trials, which typically span less than four months. Information regarding safety and effectiveness for long-term maintenance use beyond these study periods is not fully established in the core regulatory documents.


Q: Are there any specific vitamins or supplements that interact with Deprax?

A: Official documents warn about interactions with strong inhibitors of the CYP3A4 liver enzyme and other serotonergic agents. For this reason, patients are advised to tell their prescriber about all prescription and over-the-counter medicines, as well as any vitamins and supplements they use.


Q: Can Deprax be used by people with existing heart conditions?

A: Official information specifies that Deprax is not recommended during the initial recovery phase of a myocardial infarction (heart attack). For patients with other pre-existing heart conditions, the medicine must be used with caution due to the potential risk of cardiac arrhythmias (irregular heartbeat).


Q: Why are people told to avoid certain foods when taking Deprax?

A: The official guidance on food relates to the different formulations of the drug. Immediate-release tablets are recommended to be taken shortly after a meal or light snack to help optimize absorption and may also reduce potential side effects like dizziness or stomach upset.


Q: How is Deprax different from a sedative?

A: Deprax's primary approved use is for Major Depressive Disorder, and it is chemically classified as an antidepressant (SARI). Its notable sedative properties—which support its use for sleep—are the result of its action as an antagonist (blocker) at specific receptors in the brain.


Q: Does Deprax interact with common over-the-counter pain relievers like ibuprofen?

A: Yes, official warnings address this type of interaction. The combination of Deprax with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, has been associated with an increased risk of bleeding. Official guidance highlights the need for caution when combining these substances.


Q: Does Deprax come in different strengths or forms (tablet, liquid)?

A: Official documentation lists Trazodone as being available in both immediate-release (IR) tablets and extended-release (ER) tablets. These are offered in various strengths, and the tablets are often scored for precise dosing.


Q: Does Deprax interact with grapefruit or grapefruit juice?

A: Official documentation states that using Deprax with strong CYP3A4 inhibitors can significantly increase the concentration of the drug in the body. Since grapefruit is a known inhibitor of this liver enzyme, many health care providers recommend avoiding grapefruit or grapefruit juice while taking this medicine.


Q: What are the general expectations for a person starting treatment with Deprax?

A: Based on official warnings and documented adverse reactions, initial expectations include the potential for common side effects such as drowsiness, dizziness, and dry mouth. These effects may be more noticeable at the start of treatment or following dosage changes.


Q: Is Deprax a medicine that is usually taken short-term or long-term?

A: Deprax is approved for the treatment of Major Depressive Disorder, which often involves different phases of management. The core evidence supporting the drug's initial approval is derived from short-term clinical studies, typically lasting a few months.


Q: Is it safe to take herbal remedies while on Deprax?

A: Official documents explicitly warn that using Trazodone with other serotonergic drugs, which include the herbal remedy St. John's Wort, can increase the risk of a serious condition called Serotonin Syndrome. Caution is advised regarding any herbal remedies.

How should Deprax be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal instructions for Deprax (trazodone hydrochloride tablets) are strictly governed by regulatory labeling to maintain quality and safety.


Storage Conditions

Deprax must be stored at Controlled Room Temperature (CRT), which is typically defined as 20 C to 25 C (68 F to 77 F). The tablets must be kept in a tight container and protected from light.

Requirement Specific Condition
Temperature Range 20 C to 25 C (CRT)
Environmental Protection Protect from light; store in tight container
Child Safety Keep out of the reach of children

Disposal Instructions

Unused or expired Deprax should be disposed of via an official drug take-back program when available. If a take-back program is not accessible, follow the specific household disposal procedure: mix the tablets with an undesirable substance, place the mixture in a sealed container, and discard it in the trash. Disposal of the contents must adhere to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deprax found in:

A-Z Index: